OR WAIT null SECS
- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
AptarGroup Receives FDA Approval for Packaging Solution for HIV Prevention Medicine
The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging.
AptarGroup, a consumer dispensing, active packaging, and drug delivery solutions company headquartered in Crystal Lake, IL, announced its packaging solution for oral-solid-dose drug delivery, Activ-Blister, was approved by FDA for an HIV prevention medicine.
The packaging solution works to protect drugs with a 3-Phase Activ-Polymer solution, a technology that is customized for the drug developer’s formulation, offers a broad spectrum of specific drug protection, and oxygen and odor scavenging, according to an Oct. 22, 2019 press release. With the ability to maintain this technology, the Activ-Blister helps biotech and pharmaceutical companies meet long-term and in-use stability drug requirements.
“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister technology,” said Stephan Tanda, Aptar’s president and CEO, in the press release. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymer technology to help our customers with unique protective formulations that de-risk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”
Aptar will be exhibiting at Stand 111D70 at CPhI Worldwide from Nov. 5–7 in Frankfurt, Germany.
Source: Aptar
